New Cancer Vaccine Shows Promise in Treating Deadly Forms and Preventing Relapse

An off-the-shelf cancer vaccine developed by Elicio Therapeutics has shown potential to lower the risk of relapse in patients with colon and pancreatic cancers caused by the KRAS mutation, which accounts for up to 90% of cases. In an early trial, the vaccine was found to be safe and feasible, and could improve survival rates for these two deadly cancers. Unlike other experimental cancer vaccines, this vaccine does not need to be customized to each patient, making it more readily available and less expensive. The vaccine uses peptides to bind to the protein albumin, which then travels to the lymph nodes and creates white blood cells to fight off cancer markers found in the patients' blood.